Solid Biosciences
SLDB
6.85
-0.07
-1.01%
Solid Biosciences
US · SLDB
#3476 by market cap
Listed 2018
6.85
-0.07
-1.01%
Live - 5344 symbols - heartbeat 294s ago
· 2026-10-08 09:04
Pre-market
6.73
-1.75%
After-hours
6.85
0.00%
Overnight
6.87
+0.29%
- Market cap
- 734.49M
- P/E (TTM)i
- -3.62
- P/Bi
- 1.96
- EPSi
- -1.99
- Div yieldi
- 0.00%
- 52W posi
- 40%
Reader sentiment
Are you bullish or bearish on SLDB?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 1 in the most recent period (2026/Q3).
- Total institutional ownership fell 2.7 percentage points.
Institutional ownership
- Held by institutions
- 108.51% -2.66pp
- Institutions
- 185 -1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
VC/PE Fund42.21%
Mutual Fund38.81%
Hedge Fund24.16%
Public Company2.37%
Individual/Insider0.91%
Private Company0.60%
Insurance Company0.19%
Top holders as of 2026-06-30
RA Capital Management, L.P.
11.23% · 12.04M sh
Perceptive Advisors LLC
11.10% · 11.91M sh
Bain Capital Life Sciences Investors, LLC
9.15% · 9.81M sh
Artal Group S.A.
7.17% · 7.69M sh
BlackRock
6.47% · 6.93M sh
FMR
6.41% · 6.88M sh
Vanguard Capital Management, LLC
4.20% · 4.50M sh
Armistice Capital LLC
3.99% · 4.28M sh
State Street Global Advisors
3.89% · 4.18M sh
Janus Henderson Group plc
3.77% · 4.04M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 20 buys · 29 sells
| Name | Role | Stake |
|---|---|---|
| RA Capital Management, L.P. | -- | 11.23% |
| Perceptive Advisors LLC | -- | 11.10% |
| Alexander Cumbo | Chief Executive Officer | 0.22% |
| Ilan Ganot | Co-founder, Strategic Advisor to the CEO & Director | 0.14% |
| Ian Smith | Executive Chairperson | 0.13% |
| David Howton | COO & Secretary | 0.10% |
| Kevin Tan | Chief Financial Officer | 0.09% |
| Gabriel Brooks | Chief Medical Officer | 0.08% |
| Jessie Hanrahan | Chief Regulatory Officer | 0.07% |
| Paul Herzich | Chief Technology Officer | 0.07% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-01 | Ian Smith | Executive Chairperson | Derivative Exercise and Retained | +3,440 | -- |
| 2026-07-01 | Ian Smith | Executive Chairperson | Derivative Exercise and Retained | +3,440 | -- |
| 2026-06-21 | RA Capital Management, L.P. | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-06-09 | Ian Smith | Executive Chairperson | Other Derivative Acquisition | +77,500 | $6.61 |
| 2026-06-09 | Perceptive Advisors LLC | -- | Other Derivative Acquisition | +77,500 | $6.61 |
| 2026-06-09 | Martin Freed | Independent Director | Other Derivative Acquisition | +77,500 | $6.61 |
| 2026-06-09 | Sukumar Nagendran | Independent Director | Other Derivative Acquisition | +77,500 | $6.61 |
| 2026-06-09 | Ilan Ganot | Co-founder, Strategic Advisor to the CEO & Director | Other Derivative Acquisition | +77,500 | $6.61 |
| 2026-06-09 | Adam Stone | Lead Independent Director | Other Derivative Acquisition | +77,500 | $6.61 |
| 2026-06-09 | Lynne Sullivan | Independent Director | Other Derivative Acquisition | +77,500 | $6.61 |
| 2026-06-09 | Georgia Keresty | Independent Director | Other Derivative Acquisition | +77,500 | $6.61 |
| 2026-06-09 | G. Kahn | Independent Director | Other Derivative Acquisition | +77,500 | $6.61 |
| 2026-04-01 | Ian Smith | Executive Chairperson | Derivative Exercise and Retained | +3,441 | -- |
| 2026-03-08 | Joseph Edelman | -- | Other Derivative Acquisition | +8,912,655 | $0.00 |
| 2026-02-17 | David Howton | COO & Secretary | Derivative Exercise and Sale | -7,469 | $5.82 |
| 2026-02-17 | David Howton | COO & Secretary | Intent to Sell (Form 144) | -7,469 | $5.82 |
| 2026-02-17 | Ilan Ganot | Co-founder, Strategic Advisor to the CEO & Director | Derivative Exercise and Sale | -2,658 | $5.82 |
| 2026-02-17 | Ilan Ganot | Co-founder, Strategic Advisor to the CEO & Director | Intent to Sell (Form 144) | -2,658 | $5.92 |
| 2026-02-17 | Alexander Cumbo | Chief Executive Officer | Derivative Exercise and Sale | -16,644 | $5.82 |
| 2026-02-17 | Alexander Cumbo | Chief Executive Officer | Intent to Sell (Form 144) | -16,644 | $5.82 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 09:04:36 · For reference only, not investment advice and not tailored to your situation.